Composition for inhibiting IL1R1 expression and use thereof

Abstract

The present application provides a composition for inhibiting IL1R1 expression and its use, wherein the composition comprises ectoine or its derivatives and frangipani extract. The ectoine or its derivatives and frangipani extract in the present application's composition have a synergistic effect in inhibiting IL1R1 expression, which can alleviate discomfort caused by skin inflammatory factors, reduce symptoms of skin allergic reactions, and prevent or reduce problems such as skin barrier damage.

Description

Technical Field

[0001] The present application belongs to the field of cosmetic technology, and specifically relates to a composition for inhibiting IL1R1 expression and its use. Background Art

[0002] Damage to the skin barrier causes the skin to be in a sub-healthy state, which may cause tightness, stinging, burning, and may even be accompanied by symptoms such as erythema, desquamation, and vasodilation. When severely damaged, it may manifest as acne, eczema, atopic dermatitis, neurodermatitis, psoriasis, chloasma, squamous cell carcinoma of the skin, etc., seriously affecting physical and mental health. Therefore, the concept of skin repair has received widespread attention in the past two years.

[0003] Inflammatory factors are closely related to damaged skin barrier. When external stimuli are applied to the skin, the nuclear transcription factor NF-KB is upregulated, which promotes the expression of more secondary inflammatory factors in nuclear DNA: tumor necrosis factor TNF-α, inflammatory factor interleukin IL-1 and pro-inflammatory factors. These factors induce different inflammatory manifestations of the skin through signal transduction and regulatory mechanisms. The accumulation of inflammation continues in a cycle, leading to skin barrier problems.

[0004] IL-1 receptors (IL-1Rs) are present on the surface of nearly all nucleated cells. The number of IL-1Rs per cell varies, ranging from a few dozen (e.g., T cells) to thousands (e.g., fibroblasts). There are two main types of IL-1Rs: IL-1R1, which has a longer peptide chain extending into the cytoplasm and transmits activation signals; and IL-1R2, which has a shorter peptide segment within the cytoplasm and cannot effectively transmit signals. Instead, it releases the peptide segment outside the cell into the extracellular fluid, where it binds to IL-1 in a free form and exerts a feedback inhibitory effect.

[0005] Therefore, it is urgent to develop a product that can effectively inhibit the expression of IL-1R1, so as to reduce the symptoms of skin allergic reactions, prevent or reduce skin barrier damage and other problems. Summary of the Invention

[0006] The purpose of the present application is to provide a composition for inhibiting IL1R1 expression and its use.

[0007] Specifically, this application involves the following aspects:

[0008] 1. A composition for inhibiting IL1R1 expression, comprising ectoine or its derivatives and frangipani flower extract.

[0009] 2. The composition according to item 1, wherein the mass ratio of ectoine or its derivative to the frangipani flower extract is 1:200-600:1.

[0010] 3. The composition according to item 2, wherein the mass ratio of ectoine or its derivative to the frangipani flower extract is 1:1-100:1.

[0011] 4. The composition according to any one of items 1 to 3, wherein the content of ectoine or its derivative is 0.01-5 wt%, and the content of frangipani extract is 0.001-2 wt%.

[0012] 5. The composition according to any one of items 1 to 4, wherein the frangipani flower extract has a total protein content of 1-2.5 wt%, a total polyphenol content of 0.275-0.525 wt%, a total sugar content of 1-2.5 wt%, and a small molecule RNA content of >0.005 wt%.

[0013] 6. Use of the composition according to any one of items 1 to 5 for preparing a product for inhibiting IL1R1 expression.

[0014] 7. Use of the composition according to any one of items 1 to 5 as a cosmetic for inhibiting IL1R1 expression.

[0015] 8. Use of ectoine or its derivatives and / or frangipani flower extract in inhibiting IL1R1 expression, wherein the use is realized in cosmetics.

[0016] 9. Use of ectoine or its derivatives and / or frangipani flower extract as cosmetic ingredients in inhibiting IL1R1 expression.

[0017] 10. The use according to any one of items 6 to 9, which comprises reducing the symptoms of skin allergic reactions, preventing or reducing skin barrier damage,

[0018] Preferably, the allergic reaction symptoms include one or more of erythema, edema, and burning, and the skin barrier damage symptoms include one or more of acne, eczema, atopic dermatitis, and psoriasis.

[0019] The ectoine or its derivatives and the frangipani extract in the composition of the present application have a synergistic effect in inhibiting the expression of IL1R1, which can alleviate the discomfort caused by skin inflammatory factors, reduce the symptoms of skin allergic reactions, and prevent or reduce problems such as skin barrier damage. DETAILED DESCRIPTION

[0020] The present application is further described below with reference to examples. It should be understood that the examples are only used to further illustrate and explain the present application and are not intended to limit the present application.

[0021] Unless otherwise defined, technical and scientific terms used in this specification have the same meaning as those commonly understood by those skilled in the art. Although methods and materials similar or identical to those described herein may be used in experiments or practical applications, the materials and methods are described herein below. In the event of a conflict, the present specification, including definitions, will prevail. In addition, the materials, methods, and examples are provided for illustrative purposes only and are not intended to be limiting. The present application is further described below with reference to specific examples, which are not intended to limit the scope of this application.

[0022] Composition

[0023] A subject matter of this application relates to a composition. Any "composition" capable of inhibiting IL1R1 expression is sufficient. This includes, but is not limited to, using the components simultaneously or sequentially. "Simultaneous use" includes using the components together in the same formulation or separately in different formulations. "Sequential use" includes using the components sequentially in different formulations, and there is no limitation on the order of sequential use.

[0024] The present application provides a composition for inhibiting IL1R1 expression, which comprises ectoine or its derivatives and frangipani flower extract.

[0025] Among them, Ectoin, chemically known as ectoine / ectoine, has been shown to be a corticosteroid alternative for the treatment of eczema and neurodermatitis. Ectoin is also safe and approved for the treatment of inflamed and atopic infant skin. In skincare, it primarily provides repair and skin regeneration benefits, calming and soothing irritated and damaged skin, and possesses excellent anti-inflammatory properties.

[0026] The derivatives of ectoine may include one or more of ectoine methyl ester, hydroxyectoine, and salts of ectoine.

[0027] Jasminum grandiflorum L., a plant of the genus Jasminum in the family Oleaceae, is also known as Jasminum needle, Jade Hibiscus, and Yesiming flower. It is also known as Royal Jasmine abroad. It is recorded in my country's "Record of Medicinal Herbs in Lingnan" that it "relieves heart qi depression and pain, and stops diarrhea and abdominal pain." It is rich in triterpenoid saponins, flavonoid glycosides, iridoid saponins, glycosides, and phenolic compounds, and has certain efficacy properties. It is often used in health foods and scented teas, and is also being developed and utilized for medicinal purposes.

[0028] The frangipani flower extract is obtained from the frangipani flower. The frangipani flower extract of the present application is commercially available or can be extracted by a preparation method known in the art, for example, by subjecting the frangipani flower to a self-fermentation process with symbiotic bacteria and then extracting the product.

[0029] In a specific embodiment, in the frangipani flower extract, the content of total protein component is 1-2.5wt%, for example, it can be 1wt%, 1.1wt%, 1.2wt%, 1.3wt%, 1.4wt%, 1.5wt%, 1.6wt%, 1.7wt%, 1.8wt%, 1.9wt%, 2wt%, 2.1wt%, 2.2wt%, 2.3wt%, 2.4wt%, 2.5wt%, and any range between these values; the content of total polyphenol component is 0.275-0 .525wt%, for example, it can be 0.275wt%, 0.28wt%, 0.29wt%, 0.3wt%, 0.31wt%, 0.32wt%, 0.33wt%, 0.34wt%, 0.35wt%, 0.36wt%, 0.37wt%, 0.38wt%, 0.39wt%, 0.4wt%, 0.41wt%, 0.42wt%, 0.43wt%, 0.44wt%, 0.45wt%, 0.46wt%, 0.47wt%, 0.48wt %, 0.49wt%, 0.5wt%, 0.51wt%, 0.52wt%, 0.525wt%, and any ranges therebetween; the content of total sugar component is 1-2.5wt%, for example, it can be 1wt%, 1.1wt%, 1.2wt%, 1.3wt%, 1.4wt%, 1.5wt%, 1.6wt%, 1.7wt%, 1.8wt%, 1.9wt%, 2wt%, 2.1wt%, 2.2wt%, 2.3wt%, 2.4wt%, 2.5wt%, and any ranges between these values; the content of the small molecule RNA component is greater than 0.005wt%, for example, it can be 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 1.5wt%, 2wt%, 2.5wt%, 3wt%, 3.5wt%, 4wt%, 4.5wt%, 5wt%, and any ranges between these values. Furthermore, the frangipani flower extract also contains other ingredients that do not affect the efficacy of the extract, such as a solvent, which can be water.

[0030] In a specific embodiment, in the composition for inhibiting IL1R1 expression, the mass ratio of ectoine or its derivatives to the frangipani extract is 1:200-600:1, for example, 1:200, 1:150, 1:100, 1:90, 1:80, 1:70, 1:60, 1:50, 1:40, 1:30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, 150:1, 200:1, 250:1, 300:1, 350:1, 400:1, 450:1, 500:1, 550:1, 600:1, and any range therebetween.

[0031] In a specific embodiment, in the composition for inhibiting IL1R1 expression, the mass ratio of ectoine or its derivatives to the frangipani flower extract is 1:1-100:1.

[0032] In a specific embodiment, in the composition for inhibiting IL1R1 expression, the content of ectoine or its derivatives is 0.01-5wt%, for example, 0.01wt%, 0.02wt%, 0.1wt%, 0.15wt%, 2wt%, 0.25wt%, 0.3wt%, 0.35wt%, 0.4wt%, 0.45wt%, 0.5wt%, 0.45wt%, 0.5wt%, 0.55wt%, 0.6wt%, 0.65wt%, 0.7wt%, 0.75wt%, 0.8wt%, 0.85wt%, 0.9wt%, 0.95wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, etc. and any ranges between these values; the content of frangipani extract is 0.001-2wt%, for example, it can be 0.001wt%, 0.002wt%, 0.01wt%, 0.02wt%, 0.05wt%, 0.1wt%, 0.15wt%, 0.2wt%, 0.25wt%, 0.3wt%, 0.35wt%, 0.4wt%, 0.45wt%, 0.5wt%, 0.55wt%, 0.6wt%, 0.65wt%, 0.7wt%, 0.75wt%, 0.8wt%, 0.85wt%, 0.9wt%, 0.95wt%, 1wt%, 1.5wt%, 2wt%, and any ranges between these values.

[0033] In one specific embodiment, in the composition for inhibiting IL1R1 expression, the mass ratio of ectoine or its derivative to the frangipani flower extract is 1:1-100:1. The frangipani flower extract has a total protein content of 1-2.5 wt%, a total polyphenol content of 0.275-0.525 wt%, a total sugar content of 1-2.5 wt%, and a micromolecular RNA content greater than 0.005 wt%.

[0034] In one specific embodiment, the composition for inhibiting IL1R1 expression comprises 0.01-5 wt% of ectoine or its derivatives, 0.001-2 wt% of frangipani flower extract, 1-2.5 wt% of total protein, 0.275-0.525 wt% of total polyphenols, 1-2.5 wt% of total sugars, and >0.005 wt% of micromolecular RNA.

[0035] In one specific embodiment, in the composition for inhibiting IL1R1 expression, the mass ratio of ectoine or its derivatives to frangipani extract is 1:1-100:1, the content of ectoine or its derivatives is 0.01-5wt%, and the content of frangipani extract is 0.001-2wt%. The frangipani extract has a total protein content of 1-2.5wt%, a total polyphenol content of 0.275-0.525wt%, a total sugar content of 1-2.5wt%, and a small molecule RNA content greater than 0.005wt%.

[0036] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises 0.01 wt % of ectoine and 1 wt % of frangipani flower extract.

[0037] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises 0.01 wt % of ectoine and 0.2 wt % of frangipani flower extract.

[0038] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises 0.1 wt % of ectoine and 0.2 wt % of frangipani flower extract.

[0039] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises 0.1 wt % of ectoine and 0.02 wt % of frangipani flower extract.

[0040] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises 0.1 wt % of ectoine and 0.002 wt % of frangipani flower extract.

[0041] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises 1 wt % of ectoine and 0.002 wt % of frangipani flower extract.

[0042] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or a derivative thereof and frangipani flower extract, and does not comprise other active ingredients that affect IL1R1 expression.

[0043] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or its derivatives and frangipani extract, and does not include other active ingredients that affect IL1R1 expression. In the composition for inhibiting IL1R1 expression, the mass ratio of ectoine or its derivatives to frangipani extract is 1:200-600:1.

[0044] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or a derivative thereof and frangipani extract, and does not include other active ingredients that affect IL1R1 expression. In the composition for inhibiting IL1R1 expression, the mass ratio of ectoine or a derivative thereof to frangipani extract is 1:1-100:1.

[0045] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or its derivatives and frangipani flower extract, and does not include other active ingredients that affect IL1R1 expression. In the composition for inhibiting IL1R1 expression, the content of ectoine or its derivatives is 0.01-5 wt%.

[0046] In one specific embodiment, a composition for inhibiting IL1R1 expression comprises ectoine or a derivative thereof and a frangipani flower extract, and does not include any other active ingredients that affect IL1R1 expression. In the composition for inhibiting IL1R1 expression, the content of ectoine or a derivative thereof is 0.01-5wt%, and the content of the frangipani flower extract is 0.001-2wt%. The frangipani flower extract has a total protein content of 1-2.5wt%, a total polyphenol content of 0.275-0.525wt%, a total sugar content of 1-2.5wt%, and a micromolecular RNA content greater than 0.005wt%.

[0047] In one specific embodiment, a composition for inhibiting IL1R1 expression comprises ectoine or its derivatives and a frangipani flower extract, and does not include other active ingredients that affect IL1R1 expression. In the composition for inhibiting IL1R1 expression, the mass ratio of ectoine or its derivatives to the frangipani flower extract is 1:1-100:1, the content of ectoine or its derivatives is 0.01-5wt%, and the content of the frangipani flower extract is 0.001-2wt%. The frangipani flower extract has a total protein content of 1-2.5wt%, a total polyphenol content of 0.275-0.525wt%, a total sugar content of 1-2.5wt%, and a small molecule RNA content greater than 0.005wt%.

[0048] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or its derivatives and frangipani extract, and does not include other active ingredients that affect IL1R1 expression. The composition for inhibiting IL1R1 expression comprises 0.01 wt% ectoine and 1 wt% frangipani extract.

[0049] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or its derivatives and frangipani extract, and does not include other active ingredients that affect IL1R1 expression. The composition for inhibiting IL1R1 expression comprises 0.01 wt% ectoine and 0.2 wt% frangipani extract.

[0050] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or its derivatives and frangipani flower extract, and does not include other active ingredients that affect IL1R1 expression. The composition for inhibiting IL1R1 expression comprises 0.1 wt% ectoine and 0.2 wt% frangipani flower extract.

[0051] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or its derivatives and frangipani flower extract, and does not include other active ingredients that affect IL1R1 expression. The composition for inhibiting IL1R1 expression comprises 0.1 wt% ectoine and 0.02 wt% frangipani flower extract.

[0052] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or its derivatives and frangipani flower extract, and does not include other active ingredients that affect IL1R1 expression. The composition for inhibiting IL1R1 expression comprises 0.1 wt% ectoine and 0.002 wt% frangipani flower extract.

[0053] In a specific embodiment, the composition for inhibiting IL1R1 expression comprises ectoine or a derivative thereof and frangipani flower extract, and does not include other active ingredients that affect IL1R1 expression. The composition for inhibiting IL1R1 expression comprises 1 wt% ectoine and 0.002 wt% frangipani flower extract.

[0054] use

[0055] Another subject matter of this application relates to uses. The term "product" refers to any product in any formulation intended to inhibit IL1R1 expression. The term "cosmetic" refers to a preparation applied to the human body to beautify, preserve, or alter one's appearance, or to cleanse, dye, polish, correct, or protect the skin. The "cosmetics" referred to in this application do not involve any therapeutic effects.

[0056] The present application provides use of any one of the above compositions in preparing a product for inhibiting IL1R1 expression.

[0057] The present application provides use of any one of the above compositions as a cosmetic for inhibiting IL1R1 expression.

[0058] The present application also provides the use of ectoine or its derivatives and / or frangipani flower extract in preparing a product for inhibiting IL1R1 expression.

[0059] The present application also provides the use of ectoine or its derivatives and / or frangipani flower extract as cosmetic ingredients in inhibiting IL1R1 expression.

[0060] In a specific embodiment, ectoine or its derivatives and / or frangipani extract are used as active ingredients in inhibiting IL1R1 expression.

[0061] In any of the above uses, the allergic reaction symptoms may include one or more of erythema, edema, and burning. The skin barrier damage symptoms may include one or more of acne, eczema, atopic dermatitis, and psoriasis.

[0062] Example

[0063] The raw materials used in the examples and comparative examples of the present application are shown in Table 1.

[0064] Table 1

[0065]

[0066]

[0067] Example 1

[0068] Weigh Ecdoin and Caressense TMThe mixture was dissolved in PBS buffer to obtain a composition, wherein the content of ectoine in the composition was 0.01 wt %, and the content of frangipani flower extract was 1 wt %.

[0069] Example 2

[0070] Weigh Ecdoin and Caressense TM The mixture was dissolved in PBS buffer to obtain a composition, wherein the content of ectoine in the composition was 0.01 wt %, and the content of frangipani flower extract was 0.2 wt %.

[0071] Example 3

[0072] Weigh Ecdoin and Caressense TM The mixture was dissolved in PBS buffer to obtain a composition, wherein the content of ectoine in the composition was 0.1 wt %, and the content of frangipani flower extract was 0.2 wt %.

[0073] Example 4

[0074] Weigh Ecdoin and Caressense TM The mixture was dissolved in PBS buffer to obtain a composition, wherein the content of ectoine in the composition was 0.1 wt %, and the content of frangipani flower extract was 0.02 wt %.

[0075] Example 5

[0076] Weigh Ecdoin and Caressense TM The mixture was dissolved in PBS buffer to obtain a composition, wherein the content of ectoine in the composition was 0.1 wt %, and the content of frangipani flower extract was 0.002 wt %.

[0077] Example 6

[0078] Weigh Ecdoin and Caressense TM The mixture was dissolved in PBS buffer to obtain a composition, wherein the content of ectoine in the composition was 1 wt %, and the content of frangipani flower extract was 0.002 wt %.

[0079] Comparative Example 1

[0080] Ectoin was weighed and dissolved in PBS buffer to obtain a solution with an ectoin content of 0.01 wt%.

[0081] Comparative Example 2

[0082] Ectoin was weighed and dissolved in PBS buffer to obtain a solution with an ectoin content of 0.1 wt%.

[0083] Comparative Example 3

[0084] Weigh ectoine and dissolve it in PBS buffer to obtain a solution with an ectoine content of 1 wt%.

[0085] Comparative Example 4

[0086] Weigh Caressense TM The mixture was dissolved in PBS buffer to obtain a solution with a frangipani extract content of 0.002 wt%.

[0087] Comparative Example 5

[0088] Weigh Caressense TM The extract was dissolved in PBS buffer to obtain a solution with a frangipani extract content of 0.02 wt%.

[0089] Comparative Example 6

[0090] Weigh Caressense TM The extract was dissolved in PBS buffer to obtain a solution with a frangipani extract content of 0.2 wt%.

[0091] Test example

[0092] The samples prepared in the examples and comparative examples, as well as a blank sample (PBS buffer) were tested using an in vitro skin model.

[0093] 1. Materials

[0094] 1.1 In vitro skin model

[0095] Skin tissue from the abdomen of a 39-year-old female donor was obtained from a clinic. Skin biopsies were obtained using a 6 mm diameter punch (pfm medical). They were cultured in a medium containing 50% DMEM 1 g / L glucose (Lonza) and 50% Ham's-F12 (Lonza) supplemented with 10% FBS (Lonza), 2 mM glutamine (Lonza), and 100 μg / mL Primocin* (InvivoGen). Skin biopsies were maintained at 37°C in a humidified atmosphere containing 5% CO2.

[0096] 1.2 Antibodies

[0097] Antibodies: The primary antibody used in this study was rabbit anti-IL1R1 polyclonal antibody (Rockland) at a dilution of 1 / 200 for two hours. The secondary antibody used was donkey anti-mouse secondary antibody Alexa Fluor 488* (Invitrogen) at a dilution of 1 / 1000 for one hour.

[0098] 2. Test methods

[0099] 2.1 Principle: Immunofluorescence is a technique that allows the visualization of specific proteins in tissue sections by binding to specific primary antibodies. A secondary antibody labeled with a fluorescent dye is used to recognize the primary antibody. Immunofluorescence-stained samples are then examined under a fluorescence microscope. Counterstaining with DAPI allows visualization of cell nuclei.

[0100] 2.2 Sample application: Take 20 μl of sample and apply it topically on the skin biopsy twice a day for 48 hours. 24 hours after the first application of the sample, use 200 mJ / cm 2 UVB was irradiated and applied to the samples again twice a day before staining.

[0101] 2.3 Biopsy Preparation: To preserve and section the skin, the tissue was fixed in buffered 10% formalin for 4 hours. The sample was transferred to baths of increasing ethanol concentration to remove water, followed by two xylene baths to remove the alcohol, and finally embedded in molten paraffin. The embedded skin biopsies were then cut into 4 μm thick sections using a microtome (Shandon) and placed on glass slides (Thermo).

[0102] 2.4 Photo acquisition: The sections were dewaxed and rehydrated successively with xylene, alcohol, and a water bath. Antigen retrieval was then performed in 1.3 mM EDTA buffer at pH 9, with microwave irradiation at 600 W until boiling. After washing with PBS and saturating nonspecific sites with a solution of 5% BSA (Sigma) for 2 hours, the primary antibody was applied and the slides were incubated in a humid chamber with stirring at room temperature. After rinsing the slides with PBS, the secondary antibody was applied in a humid chamber with stirring in the dark at room temperature. Finally, the sections were mounted in Fluoromount-G* containing DAPI for nuclear staining (Electron Microscopy Sciences). Photos were collected using NiS AR (Nikon) acquisition software using a Nikon Eclipse Ni-E microscope equipped with a DS-Fi3 Nikon camera.

[0103] 3. Statistical analysis of results

[0104] 3.1 Image Quantization

[0105] Six photos per condition were analyzed using Volocity image analysis software (Improvision), which allows the selection of regions of interest based on fluorescence intensity. The result obtained was the sum of the green pixel intensities in the selected area. Finally, for each photo, the sum obtained was adjusted by taking into account the area of ​​the epidermal region examined.

[0106] 3.2 Jin's formula

[0107] Synergy was verified using King's formula.

[0108] Inspection formula and principles:

[0109] Q=E a+b / (E a +E b -E a ×E b )

[0110] Wherein, E(a+b) is the 1L1R1 expression inhibition rate of the combination treatment group, and Ea and Eb are the 1L1R1 expression inhibition rates after treatment with component a and component b alone, respectively.

[0111] When Q<0.55, it is obvious antagonism; when Q is 0.85-1.15, it is simple addition; when Q is greater than 1.15, it is synergistic.

[0112] The results are shown in Table 2.

[0113] Table 2

[0114]

[0115] The IL1R1 expression inhibition rate = 1 - IL1R1 expression level of the test sample / IL1R1 expression level of the blank sample treated with UV.

Claims

1. A composition for inhibiting IL1R1 expression, comprising ectoine and a frangipani extract, wherein the mass ratio of the ectoine to the frangipani extract is 1:100-500:1; The content of ectoine is 0.01-5wt%, and the content of the frangipani flower extract is 0.001-2wt%.

2. The composition according to claim 1, wherein the mass ratio of the ectoine to the frangipani flower extract is 1:1-100:

1.

3. The composition according to claim 1 or 2, wherein the frangipani flower extract has a total protein content of 1-2.5 wt%, a total polyphenol content of 0.275-0.525 wt%, a total sugar content of 1-2.5 wt%, and a small molecule RNA content of >0.005 wt%.

Images